Houston to host inaugural ESPN collegiate esports competition

Game on

ESPN's inaugural esports competition for college students is premiering at Comicpalooza. Jamie McInall/Pexels

For the first time ever, ESPN is hosting the Collegiate Esports Championship, and it's chosen Houston's 11th annual Comicpalooza to host it on May 10 to May 12 at the George R. Brown Convention Center.

"We are honored ESPN has chosen Houston and Comicpalooza for their inaugural Collegiate Esports Championship," says Michael Heckman, Comicpalooza president and senior vice president at Houston First, in a release. "Each year we strive to provide unique experiences for our different pop culture fandoms. Esports is undoubtedly popular and expanding. Teaming up with ESPN to bring the CEC here allows us to engage our audiences in a completely new, exciting way."

Students from hundreds of schools have competed to make it to the semifinals and championship in Houston, and scholarships are on the line. The weekend will have 22 teams across five video games — Hearthstone, Heroes of the Storm, Overwatch, StarCraft II, and Street Fighter V — according to ESPN.

"As universities continue to grow their esports programs at the varsity, non-varsity and club levels, we're proud to be providing a platform for national exposure and recognition of some of the most talented players in the collegiate space," says John Lasker, vice president of Digital Media Programming for ESPN, in a release. "Through our collaboration with top publishers in the industry, players will be able to showcase their talent in high-level competition on some of the most prominent esports titles."

Attendees and fans have access to the events with a Comicpalooza pass, but can also opt for the conference's Gaming Speed Pass for extra perks like reserved seating, a private lounge, and opportunities to meet the talent. Conference goers can also compete themselves in several different video games, according to the website.

Houston is a growing hub for esports. Mainline, a spin off company of Houston-based sports marketing company FanReact, launched this year to account for the growing presence of esports. Mainline's CEO, Chris Buckner, tells InnovationMap in an interview earlier this year that, especially because of this ESPN competition, other cities have their eyes on Houston for esports.

"I have been personally in contact with every major university in the city and they all are taking esports seriously," Buckner says in an interview. "It's actually a really exciting time for esports in Houston."

Chris Buckner (left), who has served as FanReact's CEO since its founding in 2014, will be the CEO of Mainline, and Patrick Schneidau has been hired to serve as CEO of FanReact. Photos courtesy

Houston startup spins off services to focus on esports and hires new CEO

CEO subs in

Houston-based FanReact LLC has decided to divide and conquer. The sports marketing and digital solutions platform announced it will spin off its Mainline business as its own company so that it can better focus on the esports market.

Chris Buckner, who has served as FanReact's CEO since its founding in 2014, will be the CEO of Mainline, and Patrick Schneidau has been hired to serve as CEO of FanReact. Both companies are evaluating which assets and employees go where, but both entities plan to hire.

"We see a tremendous opportunity for Mainline in the esports market," says Buckner in a release. "The acceleration in growth in our media and collegiate partnerships gave us the opportunity to focus exclusively on that market. At this point it makes sense to separate our Mainline business from FanReact to give each organization dedicated resources to serve our customers and partners."

Schneidau has has a long career in Houston's tech scene. He spent 12 years at Houston software company PROS and was on the leadership team when the company went public in 2007. Since he left his position as CMO at PROS, he served as the chair of the Talent Committee for Houston Exponential and serves on the board for InnovationMap.

Together, Schneidau and Buckner see the potential for Houston to rise as an epicenter for esports.

"Houston has the second highest viewership of any city in the United States behind Los Angeles," Buckner tells InnovationMap. "I think that's a product of Houston's diversity."

The spinoff allows for Buckner to focus on Mainline, which has become necessary as the business grew over time.

"The Mainline business has been so successful in recent history, that it just made sense for us to dedicate resources toward building that market," Schneidau says. "The momentum in that market as a whole — and in Mainline specifically — is just too large to ignore and not put 100 percent of Chris' time in."

Houston makes sense for an esports market, and the city is on board. ESPN's inaugural collegiate esports championship will be hosted in Houston from May 10 to 12 at the George R Brown Convention Center during the Comicpalooza weekend — and local organizations are on board with the rise of esports in Houston.

"I have been personally in contact with every major university in the city and they all are taking esports seriously," Buckner says. It's actually a really exciting time for esports in Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Modular nuclear reactor co. NuScale Power moves into Houston market

New to Hou

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

“Opening this space in Houston underscores our commitment to meeting rising energy demand with safe, scalable nuclear technology,” John Hopkins, NuScale president and CEO, said in a news release. “This move expands our presence in a key market for partners, prospective customers, and stakeholders in addition to positioning us for the future as we focus on the near-term deployment of our industry-leading technology. Texas is leading the way in embracing advanced nuclear for grid resilience and industrial decarbonization, and we’re proud to expand our footprint and capabilities in this important region.”

Interest in nuclear power has been growing in recent years thanks to tensions with oil-rich nations, concerns about man-made climate change from fossil fuels, and the rapidly increasing power needs of data centers. Both Dow and Texas A&M University have announced expanded nuclear power projects in the last year, with an eye of changing the face of Texas’s energy industry through smaller, safer fission reactors.

Enter NuScale, founded in 2007 from technology developed at the University of Oregon. Their modular SMR technology generates 77 megawatts and is one of the only small modular reactors (SMR) to receive design approval from the U.S. Nuclear Regulatory Commission (NRC). These advances have led to runaway success for NuScale, whose stock has risen by more than 1,670 percent since the start of 2024.

The new operations campus in CityCentre is expected to facilitate the movement, installation and coordination of NuScale technology into the various energy systems. Typically, SMRs are used for off-grid installations, desalination operations, mining facilities and similar areas that lack infrastructure. However, the modularity means that they can be easily deployed to a variety of areas.

It comes none too soon. ERCOT projects that Texas data centers alone will require 77,965 megawatts by 2030.

---

This article first appeared on EnergyCapitalHTX.com.

Pharma giant considers Houston for $1 billion manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Houston health tech co. lands NIH grant for AI cancer prediction tool

fresh funding

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.

View All Listings